Merck registers Phase 3 ovarian cancer trial, plus Phase 1 study of MK-1406 in healthy adults
Two new Merck Sharp & Dohme trials were posted, one testing raludotatug deruxtecan in ovarian cancer and one comparing injection regimens for MK-1406.
Merck Sharp & Dohme registered two new trials this week.
- Merck, with collaborator Daiichi Sankyo, registered a Phase 3 study called "ENGOT-ov107 / GOG-3142 / REJOICE-Ovarian05" (NCT07743164) testing raludotatug deruxtecan (R-DXd, MK-5909) with or without bevacizumab against standard platinum-based chemotherapy. The trial is aimed at patients with advanced platinum-sensitive high-grade serous or high-grade endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer who have progressed during first-line PARPi maintenance1. The study is not yet recruiting, enrollment is estimated at 646 participants1, with an estimated start date of 2026-10-05.
- Merck also registered "MK-1406-008" (NCT07743151), a Phase 1 study in healthy adults comparing subcutaneous MK-1406 given as three injections versus two injections. The trial is recruiting and aims to compare what happens to MK-1406 in the body when given as 2-injections versus 3-injections, and to learn about its safety and tolerability2, with enrollment estimated at 400 participants.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.